Proponents argue a theoretical synergy: BPC-157 is reported to upregulate VEGFR2 signaling, and TB-500/Thymosin Beta-4 is reported to sequester G-actin and upregulate VEGF — both converging on angiogenesis and tissue remodeling pathways. This is a mechanism-based hypothesis based on animal data for the component peptides, not a tested therapeutic claim for the combination.